Pharming Group N.V. - ADS, each representing 10 ordinary shares (NQ:PHAR)

A rare-disease player with a stabilized core product is now targeting a market 26 times larger, fueled by cash generation that needs no external financing.

Pharming: 3 Key Takeaways for Long-Term Investors ↗

November 04, 2026

Performance

52-Week Range 39.5% below 52-week high

12.91

9.1152W Low 21.3452W High

1 Week 1.8% below 1-week high

12.051W Low 13.141W High

Pharming Group N.V. - ADS, each representing 10 ordinary shares (PHAR) traded between $9.11 and $21.34 over the past 52 weeks and last traded at $12.91, 39.5% below its 52-week high. Over the past week it ranged between $12.05 and $13.14.

Past 12 Months

+1.4%

+31.9%

+13.7%

+2.3%

-24.7%

-26.4%

1W +$0.18

1M +$3.12

3M +$1.56

6M +$0.29

YTD -$4.23

1Y -$4.64

PHAR was -26.4% over the past year, +2.3% over six months, -24.7% year to date, +1.4% in the last week.

12 Months vs Market

PHAR

-26.4%

DIA

+9.7%

SPY

+9.8%

QQQ

+7.9%

IWM

+14.5%

Over the past 12 months PHAR returned -26.4% versus DIA (Dow) +9.7%, SPY (S&P 500) +9.8%, QQQ (Nasdaq 100) +7.9% and IWM (Russell 2000) +14.5%.

Volume & Liquidity 0.22× 3-mo avg

Today 5,559 3-mo avg 24.9K

18.2K

16.5K

24.9K

17.4K

YTD

20.3K

21.0K

PHAR most recently traded 5,559 shares against a 3-month average daily volume of 24.9K.

More News

Pharming (PHAR) Q3 2026 Earnings Call Transcript ↗

October 27, 2026

Pharming Stock Draws Retail Buzz After FDA Seeks More Data For Pediatric Immune Drug — Why Investors Aren’t Panicking ↗

February 02, 2026

Via Stocktwits

Earnings Scheduled For November 6, 2025 ↗

November 06, 2025

Via Benzinga

Pharming Group Q3 Earnings Call Highlights ↗

October 27, 2026

Via MarketBeat

Pharming Group reports third quarter 2026 financial results; strong revenue growth, Joenja APDS expansion and CVID topline data in November

October 27, 2026

Pharming Group announces third quarter 2026 revenues above market expectations

October 22, 2026

Pharming presents positive Phase II topline data for leniolisib in genetic PIDs with immune dysregulation at ESID 2026

October 14, 2026

Pharming announces CEO transition

September 29, 2026

Pharming announces U.S. FDA acceptance and Priority Review of sNDA for lower doses of Joenja® to treat children with APDS

September 25, 2026

Securities Fraud Investigation Into Pharming Group N.V. (PHAR) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm

August 06, 2026

From Glancy Prongay Wolke & Rotter LLP

Pharming Group N.V. (PHAR) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation

August 06, 2026

From Law Offices of Howard G. Smith

Securities Fraud Investigation Into Pharming Group N.V. (PHAR) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz

August 05, 2026

From The Law Offices of Frank R. Cruz

PHAR Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Pharming Group (PHAR)

August 04, 2026

From Levi & Korsinsky

Pharming (PHAR) Q2 2026 Earnings Call Transcript ↗

August 03, 2026

Pharming (PHAR) Q2 2026 Earnings Call Transcript ↗

July 30, 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pharming Group N.V. - PHAR

Pharming Group Q2 Earnings Call Highlights ↗

July 30, 2026

Via MarketBeat

Pharming Group Q1 Earnings Call Highlights ↗

May 08, 2026

Via MarketBeat

March 03, 2026

From Pomerantz LLP

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pharming Group N.V. - PHAR

February 24, 2026

From Pomerantz LLP

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pharming Group N.V. - PHAR

February 17, 2026

From Pomerantz LLP